JBC Advanced Glycation Endproducts

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M204793200 on October 9, 2002

J. Biol. Chem., Vol. 277, Issue 51, 49799-49807, December 20, 2002
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/51/49799    most recent
M204793200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shirvan, A.
Right arrow Articles by Solomon, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shirvan, A.
Right arrow Articles by Solomon, A. S.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Anti-semaphorin 3A Antibodies Rescue Retinal Ganglion Cells from Cell Death following Optic Nerve Axotomy*

Anat ShirvanDagger §, Michal Kimron, Vered Holdengreber||, Ilan ZivDagger , Yehuda Ben-Shaul||, Shlomo Melamed**, Eldad MelamedDagger , Ari BarzilaiDagger Dagger , and Arieh S. Solomon**

From the Dagger  Department of Neurology and the Felsenstein Medical Research Center, Rabin Medical Center, Beilinson Campus, and the Sackler School of Medicine, Petach Tiqva 49100 and the  Department of Neurobiochemistry, George S. Wise Faculty of Life Sciences, the || Department of Cell Research and Immunology, and the ** Sam Rothberg Glaucoma Center, Goldschleger Eye Research Institute, Tel Aviv University, Ramat Aviv, Tel Aviv 69978, Israel

Damage to the optic nerve in mammals induces retrograde degeneration and apoptosis of the retinal ganglion cell (RGC) bodies. The mechanisms that mediate the response of the neuronal cells to the axonal injury are still unknown. We have previously shown that semaphorins, axon guidance molecules with repulsive cues, are capable of mediating apoptosis in cultured neuronal cells (Shirvan, A., Ziv, I., Fleminger, G., Shina, R., He, Z., Brudo, I., Melamed, E., and Brazilai, A. (1999) J. Neurochem. 73, 961-971). In this study, we examined the involvement of semaphorins in an in vivo experimental animal model of complete axotomy of the rat optic nerve. We demonstrate that a marked induction of type III semaphorin proteins takes place in ipsilateral retinas at early stages following axotomy, well before any morphological signs of RGC apoptosis can be detected. Time course analysis revealed that a peak of expression occurred after 2-3 days and then declined. A small conserved peptide derived from semaphorin 3A that was previously shown to induce neuronal death in culture was capable of inducing RGC loss upon its intravitreous injection into the rat eye. Moreover, we demonstrate a marked inhibition of RGC loss when axotomized eyes were co-treated by intravitreous injection of function-blocking antibodies against the semaphorin 3A-derived peptide. Marked neuronal protection from degeneration was also observed when the antibodies were applied 24 h post-injury. We therefore suggest that semaphorins are key proteins that modulate the cell fate of axotomized RGC. Neutralization of the semaphorin repulsive function may serve as a promising new approach for treatment of traumatic injury in the adult mammalian central nervous system or of ophthalmologic diseases such as glaucoma and ischemic optic neuropathy that induce apoptotic RGC death.


* This work was supported in part by the National Parkinson Foundation, by the Claire and Amedee Martier Institute for the Study of Visual Disorders and Blindness, Tel Aviv University, and by the Israeli Ministry of Health (to A. B.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§ To whom correspondence may be addressed: NST Ltd., 5 Odem St., Petach Tiqva, 49170 Israel. Tel.: 972-3-921-5717; Fax: 972-3-922-7581; E-mail: anat@nst.co.il.

Dagger Dagger To whom correspondence may be addressed. Tel.: 972-3-640-9782; Fax: 972-3-640-7643; E-mail: barzilai@post.tau.ac.il.


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
S. Moretti, A. Procopio, R. Lazzarini, M. R. Rippo, R. Testa, M. Marra, L. Tamagnone, and A. Catalano
Semaphorin3A signaling controls Fas (CD95)-mediated apoptosis by promoting Fas translocation into lipid rafts
Blood, February 15, 2008; 111(4): 2290 - 2299.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
S. X. Jiang, M. Sheldrick, A. Desbois, J. Slinn, and S. T. Hou
Neuropilin-1 Is a Direct Target of the Transcription Factor E2F1 during Cerebral Ischemia-Induced Neuronal Death In Vivo
Mol. Cell. Biol., March 1, 2007; 27(5): 1696 - 1705.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
H. H. Majed, S. Chandran, S. P. Niclou, R. S. Nicholas, A. Wilkins, M. G. Wing, K. E. Rhodes, M. G. Spillantini, and A. Compston
A Novel Role for Sema3A in Neuroprotection from Injury Mediated by Activated Microglia
J. Neurosci., February 8, 2006; 26(6): 1730 - 1738.
[Abstract] [Full Text] [PDF]


Home page
GENES CELLSHome page
Y. Uchida, T. Ohshima, Y. Sasaki, H. Suzuki, S. Yanai, N. Yamashita, F. Nakamura, K. Takei, Y. Ihara, K. Mikoshiba, et al.
Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3{beta} phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease
Genes Cells, February 1, 2005; 10(2): 165 - 179.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
F. de Winter, Q. Cui, N. Symons, J. Verhaagen, and A. R. Harvey
Expression of Class-3 Semaphorins and Their Receptors in the Neonatal and Adult Rat Retina
Invest. Ophthalmol. Vis. Sci., December 1, 2004; 45(12): 4554 - 4562.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
J. L. Goldberg, M. E. Vargas, J. T. Wang, W. Mandemakers, S. F. Oster, D. W. Sretavan, and B. A. Barres
An Oligodendrocyte Lineage-Specific Semaphorin, Sema5A, Inhibits Axon Growth by Retinal Ganglion Cells
J. Neurosci., May 26, 2004; 24(21): 4989 - 4999.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Kikuchi, A. Kishino, O. Konishi, K. Kumagai, N. Hosotani, I. Saji, C. Nakayama, and T. Kimura
In Vitro and in Vivo Characterization of a Novel Semaphorin 3A Inhibitor, SM-216289 or Xanthofulvin
J. Biol. Chem., October 31, 2003; 278(44): 42985 - 42991.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Biol.Home page
C. I. Dubreuil, M. J. Winton, and L. McKerracher
Rho activation patterns after spinal cord injury and the role of activated Rho in apoptosis in the central nervous system
J. Cell Biol., July 21, 2003; 162(2): 233 - 243.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.